Blackstone Inc. acquired a new position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 499,566 shares of the company's stock, valued at approximately $1,324,000. Blackstone Inc. owned approximately 1.73% of Aerovate Therapeutics as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently modified their holdings of the company. Ieq Capital LLC bought a new position in shares of Aerovate Therapeutics in the fourth quarter worth approximately $38,000. Barclays PLC raised its position in shares of Aerovate Therapeutics by 310.8% during the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock valued at $39,000 after buying an additional 14,354 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Aerovate Therapeutics by 110.7% during the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock worth $40,000 after acquiring an additional 7,977 shares during the last quarter. Harvest Investment Services LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth $63,000. Finally, XTX Topco Ltd bought a new position in Aerovate Therapeutics in the fourth quarter valued at $63,000.
Aerovate Therapeutics Price Performance
AVTE stock traded down $0.35 during mid-day trading on Friday, hitting $8.65. 63,694 shares of the stock were exchanged, compared to its average volume of 18,165. The business has a fifty day moving average price of $75.40 and a 200 day moving average price of $84.41. Aerovate Therapeutics, Inc. has a 12 month low of $43.75 and a 12 month high of $884.98. The stock has a market capitalization of $250.72 million, a price-to-earnings ratio of -2.89 and a beta of 0.95.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported ($3.15) EPS for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. As a group, equities analysts forecast that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.
Aerovate Therapeutics Dividend Announcement
The business also recently announced a dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were paid a $84.00 dividend. The ex-dividend date of this dividend was Tuesday, April 29th.
Aerovate Therapeutics Company Profile
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
